8-K: Pulmatrix & Cullgen Waive Merger Clause, Explore Alternatives

Pulmatrix and Cullgen have mutually waived a merger clause, allowing both companies to explore alternative transactions while awaiting China Securities Regulatory Commission approval for their proposed merger.

Summary

• Pulmatrix and Cullgen Inc. have mutually waived the "No Solicitation" clause in their Merger Agreement, signed November 13, 2024, and amended April 7, 2025.
• This waiver allows both parties to explore alternative transactions while continuing to seek approval for the merger from the China Securities Regulatory Commission (CSRC).
• The Merger Agreement's Form S-4 was declared effective in May 2025, and Pulmatrix stockholders approved the merger in June 2025.
• The closing of the merger remains subject to NASDAQ listing approval and CSRC approval.
• Pulmatrix reported cash and cash equivalents of $4.8 million as of September 30, 2025, anticipating this will fund operations into at least Q4 2026.
• Pulmatrix continues to develop its iSPERSE technology and product candidates, including PUR3100 (Phase 2-ready for acute migraine), PUR1800 (Phase 1b completed for AECOPD), and PUR1900 (partner Cipla completed Phase 2 in India, approved for Phase 3, Pulmatrix to receive 2% royalties on ex-US sales).

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant delay in merger approval and the mutual waiver allowing both parties to seek alternative transactions, indicating increased uncertainty about the merger's completion. While the company has a cash runway and ongoing clinical programs, the primary strategic event (merger) is facing substantial hurdles.

Positives

• Pulmatrix's stockholders approved the merger in June 2025.
• The company's cash position of $4.8 million as of September 30, 2025, is anticipated to fund operations into at least Q4 2026.
• Pulmatrix's iSPERSE technology has a strong patent portfolio with approximately 146 granted patents and approximately 50 pending applications.
• PUR3100 is a Phase 2-ready asset for acute migraine with an accepted Investigational New Drug (IND) application and positive Phase 1 results showing targeted therapeutic range, rapid onset, and lower incidence of nausea.
• PUR1800 completed a Phase 1b study for AECOPD, demonstrating it was well-tolerated with no observed safety signals.
• Partner Cipla has completed Phase 2 for PUR1900 in India and received approval to proceed with a Phase 3 clinical trial, potentially leading to 2% royalties for Pulmatrix on ex-US sales.

Negatives

• The proposed merger with Cullgen has not yet received approval from the China Securities Regulatory Commission (CSRC), leading to a delay in closing.
• The mutual waiver of the "No Solicitation" clause indicates uncertainty regarding the merger's completion and suggests both parties are actively seeking alternative transactions.

Risks

• Uncertainty regarding the consummation and exact timing of the proposed merger with Cullgen.
• Risk of not receiving applicable regulatory approvals (e.g., CSRC, NASDAQ) for the merger.
• Ability to divest clinical assets on terms favorable to the company, or at all.
• Maintaining compliance with the listing standards of the Nasdaq Capital Market.
• Ability to conduct business and raise capital in the future when needed.
• Potential delays in planned clinical trials.
• Ability to establish that potential products are efficacious or safe in preclinical or clinical trials.
• Ability to establish or maintain collaborations on the development of therapeutic candidates.
• Ability to obtain appropriate or necessary governmental approvals to market potential products.
• Ability to obtain future funding for developmental products and working capital on commercially reasonable terms.
• Ability to manufacture product candidates on a commercial scale or in collaborations with third parties.
• Changes in the size and nature of competitors.
• Ability to retain key executives and scientists.
• Ability to secure and enforce legal rights related to the company's products, including patent protection.

Future Outlook

Pulmatrix anticipates that its current cash position of $4.8 million will be sufficient to fund operations into at least the fourth quarter of 2026. The company continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission while also exploring opportunistic alternative transactions. Clinical development for PUR3100 (Phase 2) and PUR1800 (further development for AECOPD) is ongoing, and partner Cipla is advancing PUR1900 into Phase 3 trials outside the U.S.

Management Comments

• "Regarding the Merger Agreement that we signed in November 2024, our Form S-4 filing was declared effective in May 2025, and our stockholders approved the Merger Agreement and related transactions in June 2025. However, we have not yet received approval from the CSRC."
• "Therefore, we feel that it is appropriate to explore any opportunistic transactions that may benefit our respective companies while still seeking approval from the CSRC." (Peter Ludlum, Interim Chief Executive Officer of Pulmatrix)

Industry Context

The biopharmaceutical industry frequently sees mergers and acquisitions as a strategy for growth, pipeline expansion, or market consolidation. Delays in regulatory approvals, especially from international bodies like the CSRC, are common and can significantly impact deal timelines. The mutual waiver to explore alternatives suggests a pragmatic approach to mitigate risks associated with prolonged regulatory processes, reflecting a broader trend where companies maintain flexibility in uncertain M&A environments. The continued development of iSPERSE technology and its product candidates (migraine, COPD, antifungal) positions Pulmatrix in competitive therapeutic areas, where novel drug delivery systems are increasingly valued for improving patient outcomes and reducing side effects.

Stakeholder Impact

• Shareholders: Increased uncertainty regarding the merger's completion could lead to volatility in share price. The exploration of alternative transactions might offer new strategic directions or potential value, but also introduces new unknowns.
• Employees: The delay and potential for alternative transactions could create uncertainty regarding future employment and organizational structure, especially if the merger does not proceed.
• Customers/Patients: Continued development of clinical assets like PUR3100, PUR1800, and PUR1900 suggests ongoing efforts to bring new treatments to market, which could benefit patients.
• Partners (Cullgen, Cipla): Cullgen faces similar uncertainty regarding the merger. Cipla's continued progress with PUR1900 in India is positive for their partnership.

Next Steps

• Continue working toward merger approval from the China Securities Regulatory Commission (CSRC).
• Explore opportunistic alternative transactions for both Pulmatrix and Cullgen.
• Pulmatrix to continue development of PUR3100 (Phase 2 study for acute migraine).
• Pulmatrix to continue development of PUR1800 for AECOPD and other inflammatory respiratory diseases.
• Cipla to proceed with Phase 3 clinical trial for PUR1900 in India.
• Pulmatrix and Cipla to seek to monetize PUR1900 for indications within the United States.

Key Dates

Recommendation

The mutual waiver of the "No Solicitation" clause and the ongoing delay in CSRC approval for the Cullgen merger introduce significant uncertainty regarding Pulmatrix's strategic direction. While the company has a decent cash runway into Q4 2026 and a pipeline of clinical assets (PUR3100, PUR1800, PUR1900 with Cipla), the primary catalyst for the stock (the merger) is now in question, with both parties actively seeking alternatives. This situation warrants a "hold" recommendation as investors should await clearer outcomes regarding the merger or any alternative transactions before making further investment decisions. The current situation presents both risks and potential opportunities from alternative deals, making a definitive "buy" or "sell" premature.

Keywords

Pulmatrix, Cullgen, Merger Agreement, Waiver Agreement, SEC Filing, 8-K, Biopharmaceutical, iSPERSE technology, PUR3100, PUR1800, PUR1900, Migraine, COPD, Antifungal, Clinical Trials, NASDAQ, CSRC, Corporate Governance